Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I

04-Jan-2024 - Evotec SE and Owkin, a French-American techbio startup announced an A.I.-powered integrated multi-target collaboration in oncology, immunology and inflammation (“I&I”). The collaboration brings together highly complementary platforms and expertise to accurately select targets, discover and ...

Cellectis enters into strategic collaboration and investment agreement with AstraZeneca

Cellectis to receive up to $245M in cash, with potential for additional milestones, plus tiered royalties

03-Nov-2023 - Cellectis announced it has entered into (i) a Joint Research Collaboration Agreement (the “Collaboration Agreement”, (ii) an investment agreement relating to an initial equity investment of $80M, and (iii) a memorandum of understanding (the “MOU”) relating to an additional equity investment of ...

Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery

Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success

20-Sep-2023 - Merck announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts. The partnerships, with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., ...

Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies

Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors

28-Aug-2023 - Mysthera Therapeutics AG, a company developing first-in-class, oral therapeutics to treat complex autoimmune diseases, launched with $3.5 million seed capital from founding investor Forty51 Ventures. The capital will be used to advance its portfolio of pre-clinical stage, pan-PIM kinase ...

The Jung Foundation for Science and Research awards the 2023 Jung Prize for Medicine to Özlem Türeci

Stefan Rose-John receives a prize for his life’s work and Achmed Mrestani is awarded as young researcher

04-May-2023 - New treatments against cancer, autoimmune diseases, migraine and epilepsy – these are some of the areas covered by the research results of this year’s award winners from the Jung Foundation for Science and Research. With their groundbreaking work, Professor Özlem Türeci, Professor Stefan ...

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences

18-Apr-2023 - Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. (Prometheus) announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity ...

Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology

Merck shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity

22-Nov-2022 - To achieve the goal of introducing one new product or major indication every 1.5 years on average, the company will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an ...

PhoreMost enters multi-project drug target discovery collaboration with Roche

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Roche’s discovery programmes

07-Sep-2022 - PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has entered into a multi-project target discovery collaboration with Roche. Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for ...

The human immune system is an early riser

Scientists show that activation of the immune system oscillates throughout the day, with a peak just before the start of the day

21-Oct-2021 - Circadian clocks, which regulate most of the physiological processes of living beings over a rhythm of about 24 hours, are one of the most fundamental biological mechanisms. By deciphering the cell migration mechanisms underlying the immune response, scientists from the University of Geneva ...